Výsledky vyhledávání - "Kristina Denic"

Akademický článek

A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514

Autor: Stuart L. Cramer, Alyssa Terry Reddy, Charles Gene Minard, Stephan Voss, Elizabeth Fox, Xiaowei Liu, Kristina Denic, Joel M. Reid, Brenda J. Weigel

Publikováno v: Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)

ABSTRACT Background Nab‐sirolimus (ABI‐009, nab‐rapamycin; Aadi Bioscience Inc. [Aadi]) is a human albumin‐bound form of sirolimus nanoparticles, a potent mTOR inhibitor. This phase I trial was conducted to define dose‐limiting toxicities (

Externí odkaz: https://doaj.org/article/dd2e1f92a073437a871a697c5f52e013

Zobrazit plný text záznamu

Plný text ve formátu HTML

785 A phase I study of intralymphatic (IL) administration of ipilimumab (IPI) with intravenous nivolumab (NIVO) using the Sofusa® DoseConnect™ device in patients with advanced melanoma

Autor: Anastasios Dimou, Vera Suman, Kristina Denic, Lisa Kottschade, Heather Montane, Heidi Finnes, Kristina Franta, Jill Schimke, Yiyi Yan, Robert McWilliams, Matthew Block, James Jakub, Joel Reid, Svetomir Markovic

Publikováno v: Regular and Young Investigator Award Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::572591bb65e848baa2fe52d134c0bcec
https://doi.org/10.1136/jitc-2022-sitc2022.0785

Zobrazit plný text záznamu

Biochemical liver function tests parameters do not indicate any difference in the degree of hepatotoxicity in patients with metastatic colorectal carcinoma treated with conventional anticancer drugs regardless the use of bevacizumab

Autor: Dino Tarabar, Nemanja Stanic, Slobodan Obradovic, Jelena Spasic, Nenad D. Ugrešić, Kristina Denic

Publikováno v: Vojnosanitetski pregled. 74:757-762

Background/Aim. Colorectal carcinoma (CRC) is one the most frequent malignant disease with early liver metastasis. It requires the timely use of anticancer drugs. Current treatment of metastatic CRC consists of conventional anticancer drugs use, but

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::136b7448e29828a06906dc837764f51f
https://doi.org/10.2298/vsp150807221d

Zobrazit plný text záznamu

Biochemical liver function test parameter levels in relation to treatment response in liver metastatic colorectal patients treated with FOLFOX4 with or without bevacizumab

Autor: Jelena Spasic, Slobodan Obradovic, Marija Ristic, Davorin Radosavljevic, Kristina Denic, Nenad Ugresic, Dino Tarabar

Publikováno v: Srpski Arhiv za Celokupno Lekarstvo, Vol 144, Iss 11-12, Pp 615-620 (2016)

Introduction. Combined use of bevacizumab and conventional anticancer drugs leads to a significant improvement of treatment response in patients with metastatic colorectal carcinoma (CRC). Conventional treatment protocols exert undesired effects on t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52e22ef43a190be822e9c87aa53df0a6
https://pubmed.ncbi.nlm.nih.gov/29659222

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání